InsiderPulse| Date | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-28 | Rhodes Jason P | Director | Sale | 227.3K | $18.38 | $4.18M | 8,511 | View ↗ | |
| 2026-04-27 | Rhodes Jason P | Director | Sale | 173.5K | $18.15 | $3.15M | 9,682 | View ↗ | |
| 2026-04-24 | Rhodes Jason P | Director | Sale | 137.9K | $18.48 | $2.55M | 10.6K | View ↗ | |
| 2026-04-23 | Rhodes Jason P | Director | Sale | 73.1K | $19.19 | $1.40M | 11.3K | View ↗ | |
| 2026-04-22 | Kersten Dirk | Director | Sale | 2,652 | $20.00 | $53K | 4.20M | View ↗ |
No annual data found.
Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Could Dyne Therapeutics’ (DYN) AMCP Spotlight Reveal How New FDA Leadership May Shape Its Pipeline?
Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines